{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T03:21:25Z","timestamp":1787628085842,"version":"build-2736575974"},"reference-count":31,"publisher":"American Medical Association (AMA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2019,1,1]]},"DOI":"10.1001\/jamadermatol.2018.3958","type":"journal-article","created":{"date-parts":[[2018,11,26]],"date-time":"2018-11-26T22:34:48Z","timestamp":1543271688000},"page":"22","source":"Crossref","is-referenced-by-count":34,"title":["Economic Evaluation of Talimogene Laherparepvec Plus Ipilimumab Combination Therapy vs Ipilimumab Monotherapy in Patients With Advanced Unresectable Melanoma"],"prefix":"10.1001","volume":"155","author":[{"given":"Abdulaali R.","family":"Almutairi","sequence":"first","affiliation":[{"name":"Center for Health Outcomes and PharmacoEconomic Research, College of Pharmacy, The University of Arizona, Tucson"},{"name":"Department of Pharmacy Practice and Science, College of Pharmacy, The University of Arizona, Tucson"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nimer S.","family":"Alkhatib","sequence":"additional","affiliation":[{"name":"Center for Health Outcomes and PharmacoEconomic Research, College of Pharmacy, The University of Arizona, Tucson"},{"name":"Department of Pharmacy Practice and Science, College of Pharmacy, The University of Arizona, Tucson"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mok","family":"Oh","sequence":"additional","affiliation":[{"name":"Center for Health Outcomes and PharmacoEconomic Research, College of Pharmacy, The University of Arizona, Tucson"},{"name":"Department of Pharmacy Practice and Science, College of Pharmacy, The University of Arizona, Tucson"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Curiel-Lewandrowski","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Department of Medicine, College of Medicine, The University of Arizona, Tucson"},{"name":"The University of Arizona Cancer Center, Tucson"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hani M.","family":"Babiker","sequence":"additional","affiliation":[{"name":"The University of Arizona Cancer Center, Tucson"},{"name":"Division of Hematology-Oncology, Department of Medicine, College of Medicine, The University of Arizona, Tucson"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee D.","family":"Cranmer","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Medicine, University of Washington, Seattle"},{"name":"Seattle Cancer Care Alliance, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"McBride","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice and Science, College of Pharmacy, The University of Arizona, Tucson"},{"name":"The University of Arizona Cancer Center, Tucson"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivo","family":"Abraham","sequence":"additional","affiliation":[{"name":"Center for Health Outcomes and PharmacoEconomic Research, College of Pharmacy, The University of Arizona, Tucson"},{"name":"Department of Pharmacy Practice and Science, College of Pharmacy, The University of Arizona, Tucson"},{"name":"The University of Arizona Cancer Center, Tucson"},{"name":"Department of Family and Community Medicine, College of Medicine, The University of Arizona, Tucson"},{"name":"Matrix45, Tucson, Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"1","key":"doi180059r1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.v68.1","article-title":"Cancer statistics, 2018.","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"doi180059r2","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1093\/jnci\/djq495","article-title":"Projections of the cost of cancer care in the United States: 2010-2020.","volume":"103","author":"Mariotto","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"doi180059r3","doi-asserted-by":"crossref","DOI":"10.1007\/s10585-018-9890-1","article-title":"Regional therapies for locoregionally advanced and unresectable melanoma.","author":"Weitman","year":"2018","journal-title":"Clin Exp Metastasis"},{"issue":"12","key":"doi180059r5","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1007\/s40265-018-0945-z","article-title":"Metastatic melanoma: recent therapeutic progress and future perspectives.","volume":"78","author":"Malissen","year":"2018","journal-title":"Drugs"},{"issue":"24","key":"doi180059r6","doi-asserted-by":"publisher","first-page":"6258","DOI":"10.1158\/1078-0432.CCR-14-1457","article-title":"Immuno-oncology combinations: a review of clinical experience and future prospects.","volume":"20","author":"Antonia","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"17","key":"doi180059r7","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1200\/JCO.2017.73.7379","article-title":"Randomized, open-label phase II study evaluating the efficacy and safety of talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone in patients with advanced, unresectable melanoma.","volume":"36","author":"Chesney","year":"2018","journal-title":"J Clin Oncol"},{"issue":"7695","key":"doi180059r8","doi-asserted-by":"publisher","first-page":"S26","DOI":"10.1038\/d41586-018-02483-3","article-title":"Bringing down the cost of cancer treatment.","volume":"555","author":"Dolgin","year":"2018","journal-title":"Nature"},{"issue":"6","key":"doi180059r10","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/j.socscimed.2011.01.008","article-title":"Economic evaluation to inform health care decision-making: promise, pitfalls and a proposal for an alternative path.","volume":"72","author":"Brousselle","year":"2011","journal-title":"Soc Sci Med"},{"issue":"4","key":"doi180059r11","first-page":"269","article-title":"Design, implementation, and first-year outcomes of a value-based drug formulary.","volume":"21","author":"Sullivan","year":"2015","journal-title":"J Manag Care Spec Pharm"},{"issue":"4","key":"doi180059r14","first-page":"204","article-title":"Estimating the costs of therapy in patients with relapsed and\/or refractory multiple myeloma: a model framework.","volume":"8","author":"Roy","year":"2015","journal-title":"Am Health Drug Benefits"},{"issue":"2","key":"doi180059r15","doi-asserted-by":"publisher","first-page":"202","DOI":"10.3111\/13696998.2012.739226","article-title":"Ipilimumab in 2nd line treatment of patients with advanced melanoma: a cost-effectiveness analysis [published correction appears in J Med Econ. 2013;16(2):212].","volume":"16","author":"Barzey","year":"2013","journal-title":"J Med Econ"},{"issue":"25","key":"doi180059r16","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene laherparepvec improves durable response rate in patients with advanced melanoma.","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J Clin Oncol"},{"issue":"8","key":"doi180059r17","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma [published correction appears in N Engl J Med. 2010;363(13):1290].","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"issue":"9","key":"doi180059r18","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1056\/NEJMp1405158","article-title":"Updating cost-effectiveness: the curious resilience of the $50,000-per-QALY threshold.","volume":"371","author":"Neumann","year":"2014","journal-title":"N Engl J Med"},{"issue":"2","key":"doi180059r19","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1586\/14737167.8.2.165","article-title":"Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold.","volume":"8","author":"Grosse","year":"2008","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"3","key":"doi180059r21","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/nm0313-248","article-title":"Report triggers quibbles over QALYs, a staple of health metrics.","volume":"19","author":"Holmes","year":"2013","journal-title":"Nat Med"},{"issue":"8","key":"doi180059r22","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1038\/bjc.2015.65","article-title":"Economic evaluation for the UK of nab-paclitaxel plus gemcitabine in the treatment of metastatic pancreas cancer.","volume":"112","author":"Gharaibeh","year":"2015","journal-title":"Br J Cancer"},{"issue":"11","key":"doi180059r23","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.6004\/jnccn.2016.0155","article-title":"Arguing (about) the value of cancer care.","volume":"14","author":"Abraham","year":"2016","journal-title":"J Natl Compr Canc Netw"},{"issue":"26","key":"doi180059r24","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1056\/NEJMp1011024","article-title":"What is value in health care?","volume":"363","author":"Porter","year":"2010","journal-title":"N Engl J Med"},{"issue":"6","key":"doi180059r25","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1634\/theoncologist.2016-0177","article-title":"New frameworks to assess value of cancer care: strengths and limitations.","volume":"21","author":"Schnipper","year":"2016","journal-title":"Oncologist"},{"issue":"23","key":"doi180059r26","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.1200\/JCO.2015.61.6706","article-title":"American Society of Clinical Oncology statement: a conceptual framework to assess the value of cancer treatment options.","volume":"33","author":"Schnipper","year":"2015","journal-title":"J Clin Oncol"},{"issue":"24","key":"doi180059r27","doi-asserted-by":"publisher","first-page":"2925","DOI":"10.1200\/JCO.2016.68.2518","article-title":"Updating the American Society of Clinical Oncology value framework: revisions and reflections in response to comments received.","volume":"34","author":"Schnipper","year":"2016","journal-title":"J Clin Oncol"},{"issue":"8","key":"doi180059r28","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1093\/annonc\/mdv249","article-title":"A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS).","volume":"26","author":"Cherny","year":"2015","journal-title":"Ann Oncol"},{"key":"doi180059r4","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology on melanoma. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/melanoma.pdf. Published 2018. Accessed August 27, 2018."},{"key":"doi180059r9","unstructured":"President\u2019s Cancer Panel. Promoting value, affordability, and innovation in cancer drug treatment. https:\/\/prescancerpanel.cancer.gov\/report\/drugvalue\/. Published 2018. Accessed August 27, 2018."},{"key":"doi180059r12","unstructured":"IBM Watson Health, Drug References RED BOOK. Thomson Reuters Micromedex Clinical Evidence Solutions. http:\/\/micromedex.com\/products\/product-suites\/clinical-knowledge\/redbook. Accessed January 4, 2018."},{"key":"doi180059r13","unstructured":"Centers for Medicare & Medicaid Services. Physician Fee Schedule Search Tool. https:\/\/www.cms.gov\/apps\/physician-fee-schedule\/search\/search-criteria.aspx. Accessed January 4, 2018."},{"key":"doi180059r20","unstructured":"European Consortium in Healthcare Outcomes and Cost-Benefit Research. Final report summary. https:\/\/cordis.europa.eu\/result\/rcn\/57938_en.html. Published 2013. Accessed August 27, 2018."},{"key":"doi180059r29","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) with NCCN Evidence Blocks. https:\/\/www.nccn.org\/evidenceblocks\/. Accessed August 27, 2018."},{"key":"doi180059r30","unstructured":"Institute for Clinical and Economic Review. ICER value assessment framework. https:\/\/icer-review.org\/methodology\/icers-methods\/icer-value-assessment-framework\/. Accessed August 27, 2018."},{"key":"doi180059r31","unstructured":"Memorial Sloan Kettering Drug Pricing Lab. Drug Abacus. https:\/\/drugpricinglab.org\/tools\/drug-abacus\/. Accessed August 27, 2018."}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2715092","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,9]],"date-time":"2019-01-09T20:31:20Z","timestamp":1547065880000},"score":1,"resource":{"primary":{"URL":"http:\/\/archderm.jamanetwork.com\/article.aspx?doi=10.1001\/jamadermatol.2018.3958"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,1]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2018.3958","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1,1]]}}}